Dr. Richard Drake received his Ph.D. from the University of Kentucky in Biochemistry and Molecular Biology. He did his Post-doctoral training in Glycobiology with Alan Elbein at the University of Texas Health Science Center at San Antonio, TX. Dr. Drake is currently a Professor at the Medical University of South Carolina in the Department of Pharmacology and Immunology and is the SmartState Endowed Chair in Proteomics. He has a long research history and expertise in glycomic Mass Spectrometry Imaging of tumor tissues and biomarker discovery from clinical fluids. His current efforts are in the large scale application of N-glycan Mass Spectrometry Imaging methods developed in his laboratory which utilized PNGase F PRIME™ for prostate, pancreas, liver, kidney, colon, and breast tumors. The goal is to develop glycan biomarkers associated with tumor, stroma, and immune regions of tumors, combined with other spatial-omic workflows. Dr. Drake was a co-founder and former CEO of Glycopath, a glycan diagnostic company sold to Bruker Corporation.